Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)

Published: 6 Mar-2012

DOI: 10.3833/pdr.v2012.i3.1692     ISSN: 1756-7874

Section: Distribution & Marketing

Fulltext:

Abstract

Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details